for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BB BIOTECH AG

BION.S

Latest Trade

66.10CHF

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

59.00

 - 

73.65

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Latest Developments

BB Biotech FY 2019 Net Gain Of CHF 677 Mln

Jan 17 (Reuters) - BB BIOTECH AG <BION.S>::BB BIOTECH BENEFITS FROM M&A TRANSACTIONS - DIVIDEND OF CHF 3.40 PROPOSED.CONSOLIDATED, BUT NOT YET AUDITED Q4 2019 DATA FOR BB BIOTECH INDICATES A NET GAIN OF CHF 505 MN VERSUS 2018 Q4 LOSS OF CHF 643 MN.CONSOLIDATED, BUT NOT YET AUDITED FULL YEAR 2019 DATA SHOWED A NET GAIN OF CHF 677 MN COMPARED TO A NET LOSS OF CHF 471 MN FOR 2018.OUTLOOK FOR 2020 - SECTOR FUNDAMENTALS ARE EXCITING, TRANSACTION MOMENTUM IS EXPECTED TO CONTINUE.

BB Biotech Expands Board Of Directors

Nov 20 (Reuters) - BB Biotech AG <BION.S>::DGAP-ADHOC: BB BIOTECH AG: EXPANSION OF THE BOARD OF DIRECTORS.IS NOMINATING SUSAN GALBRAITH AND MADS KROGSGAARD THOMSEN FOR ELECTION TO BOARD OF DIRECTORS.

BB Biotech Q3 Net Loss At CHF 382 Mln

Oct 18 (Reuters) - BB BIOTECH AG <BION.S>::NET PROFIT FOR PERIOD ENDED SEPTEMBER 30, 2019 AMOUNTED TO CHF 172 MN (PROFIT OF CHF 172 MN IN SAME PERIOD 2018).IN Q3 A LOSS OF CHF 382 MN (PROFIT OF CHF 242 MN IN CORRESPONDING PERIOD OF PREVIOUS YEAR).

BB Biotech Sees Portfolio Cos To Report Q4 Pipeline Progress

Oct 18 (Reuters) - BB BIOTECH AG <BION.S>::EXPECTS PORTFOLIO COMPANIES TO REPORT SUBSTANTIAL PIPELINE PROGRESS DURING Q4.

BB Biotech H1 Net Profit At CHF 554 Mln

July 19 (Reuters) - BB BIOTECH AG <BION.S>::CONSOLIDATION LEAVES A MARK ON RESULTS IN THE SECOND QUARTER.Q2 NET ASSET VALUE FELL 9.4% IN CHF AND 8.8% IN EUR, RESULTING IN A SECOND-QUARTER NET LOSS OF CHF 336 MN COMPARED TO A LOSS OF CHF 98 MN IN YEAR-AGO PERIOD.ANTICIPATES FURTHER PIPELINE PROGRESS.NET PROFIT FOR PERIOD ENDED JUNE 30, 2019 AMOUNTED TO CHF 554 MN (LOSS OF CHF 70 MN IN H1 2018).

BB Biotech Q1 Profit Of CHF 890 Million

April 26 (Reuters) - BB Biotech AG <BION.S>::Q1 PROFIT OF CHF 890 MN (PROFIT OF CHF 28 MN IN CORRESPONDING PERIOD OF PREVIOUS YEAR).

BB Biotech Launches New Buyback Program

April 12 (Reuters) - BB Biotech AG <BION.S>::SAID ON THURSDAY CONCLUDES ITS SHARE BUYBACK PROGRAM AND LAUNCHES A NEW BUYBACK PROGRAM.CONCLUDED THE SHARE BUYBACK PROGRAM IT HAD INITIATED ON APRIL 12, 2016. DURING THIS PERIOD NO REGISTERED SHARES WERE REPURCHASED VIA A SECOND TRADING LINE.DECIDED TO LAUNCH A NEW SHARE REPURCHASE PROGRAM IMMEDIATELY AFTER THE CONCLUSION OF THIS BUYBACK PROGRAM.AUTHORIZED TO REPURCHASE UP TO 10% OF ITS SHARES (5 540 000 SHARES) OVER A PERIOD OF 36 MONTHS.

BB Biotech FY Net Result Swings To Loss Of CHF 471 Million

Feb 15 (Reuters) - BB Biotech AG <BION.S>::FY NET LOSS OF CHF 471 MN COMPARED TO A NET GAIN OF CHF 688 MN FOR FULL YEAR OF 2017.

BB Biotech FY Net Result Swings To Loss Of CHF 471 Million

Jan 18 (Reuters) - BB Biotech AG <BION.S>::BB BIOTECH INVESTS GAINS OF M&A TRANSACTIONS IN NEW TECHNOLOGIES - DIVIDEND OF CHF 3.05 PROPOSED.NET LOSS OF CHF 643 MN FOR Q4 AND CHF 471 MN FOR YEAR AS A WHOLE.

BB Biotech AG posts 2018 Loss Of around CHF 471 Million

Jan 18 (Reuters) - BB Biotech AG <BION.S>::SAYS CLOSED ITS FISCAL YEAR 2018 WITH A LOSS OF APPROXIMATELY CHF 471 MILLION, BASED ON ITS PRELIMINARY UNAUDITED CONSOLIDATED RESULTS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up